Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Autolus Therapeutics ( (AUTL) ) has provided an announcement.
On May 23, 2025, Drs. Joseph Anderson and Martin Murphy announced their decision not to seek re-election to the Board of Directors of Autolus Therapeutics at the upcoming Annual General Meeting. Their resignation is not due to any disagreements with the company’s management or board, suggesting a smooth transition and stability within the company’s governance structure.
The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.
Spark’s Take on AUTL Stock
According to Spark, TipRanks’ AI Analyst, AUTL is a Neutral.
Autolus Therapeutics is experiencing strong revenue growth and strategic geographic expansion, notably with AUCATZYL. However, the financial performance indicates significant profitability and cash flow challenges. Technical indicators suggest caution, and while corporate events bolster future prospects, financial sustainability issues and a negative P/E ratio weigh heavily on the stock’s overall score.
To see Spark’s full report on AUTL stock, click here.
More about Autolus Therapeutics
Average Trading Volume: 1,973,309
Technical Sentiment Signal: Sell
Current Market Cap: $465.7M
For an in-depth examination of AUTL stock, go to TipRanks’ Stock Analysis page.